The FDA is holding a public advisory committee meeting next month to discuss whether the categorisation of Dexcom's G5 Mobile Continuous Glucose Monitoring System (CGM) can change from a tracking device only to a blood glucose meter that can be used for treatment decisions. So, I think the dosing claim could actually be a bigger catalyst than maybe we had anticipated in the past. In its submission to the FDA's review committee, Dexcom said it was "committed to providing patients with an easy, convenient and affordable option to monitor their own health status in real time."
The FDA is holding a public advisory committee meeting next month to discuss whether the categorisation of Dexcom's G5 Mobile Continuous Glucose Monitoring System (CGM) can change from a tracking device only to a blood glucose meter that can be used for treatment decisions. In its submission to the FDA's review committee, Dexcom said it was "committed to providing patients with an easy, convenient and affordable option to monitor their own health status in real time."